A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Inclusion criteria

• Voluntarily sign the informed consent form.
• Age ≥18 years, with no gender restriction.
• Pathologically confirmed patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL).
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.
• Expected survival >3 months.
• Presence of measurable lesions.
• Adequate organ function.
• Agreement to undergo pathological tissue biopsy.
• Subjects of childbearing potential must agree to comply with the contraceptive requirements of the study.
• No pregnancy plans from screening until at least 3 months after the last dose of the study drug, and voluntary use of effective contraceptive measures.

Exclusion criteria

• Concurrent presence of other severe, unstable diseases/conditions that, in the investigator's judgment, make participation in this study unsuitable.
• History of or current severe cardiovascular disease.
• Poorly controlled blood pressure during the screening period.
• Laboratory abnormalities identified by the investigator that may pose a risk to the subject's safety.
• Electrocardiogram abnormalities determined by the investigator as potentially posing a risk to the subject's safety.
• History of allergies to the investigational drug or its excipients.
• Inability to discontinue prohibited medications as specified in the protocol during the screening period and throughout the entire study duration.
• Any other conditions that may increase subject risk or interfere with the trial results.
• Any other situations where the investigator deems the subject unsuitable for participation.